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Introduction: Constipation is a distressing side effect of opioid treatment, being so irksome 
in some cases that patients would rather suffer the pain than the side effect of opioid analgesics. 
Stool softeners or stimulating laxatives are often ineffective or even aggravate the situation. 
A new efficacious and safe drug is needed to limit the frequently observed side effects induced 
by effective opioid-based analgesic therapy and to improve the quality of life for patients, most 
of whom are impaired by a severe disease.
Aims: The purpose of this article is to assess current evidence supporting the use of the 
peripherally acting µ-opioid receptor antagonist, methylnaltrexone, to restrict passage across 
the blood–brain barrier in patients with opioid-induced bowel dysfunction.
Evidence review: There are now convincing data from phase II and multicenter phase III 
randomized, double-blind, placebo-controlled trials that methylnaltrexone induces laxation in 
patients with long-term opioid use without affecting central analgesia or precipitation of opioid 
withdrawal. Onset of the effect is rapid and improvement is maintained for at least 3 months 
during the drug treatment. The action of methylnaltrexone is dose dependent. Weight-related 
dosing appeared to be effective. There were no severe side effects or signs of opioid withdrawal. 
Adverse events, most frequently abdominal cramping or nausea, were usually mild to moderate. 
Methylnaltrexone is contraindicated in patients with known or suspected mechanical intestinal 
stenosis. Patients receiving methylnaltrexone must be monitored.
Place in therapy: Methylnaltrexone applied subcutaneously every other day may be given to 
patients suffering from chronic constipation due to opioid therapy for whom laxatives do not 
provide adequate relief of their symptoms.
Keywords: constipation, methylnaltrexone, opioid-induced bowel dysfunction, opioid 
analgesics, chronic severe pain
Core evidence summary for methylnatrexon in the management of opioid-induced 
constipation
Outcome measure Evidence Implications
reduction in hospitalization No evidence
improvement of quality of life weak evidence Patients more content with bowel 
habits
Patient-oriented evidence
Methylnaltrexone accelerates opioid-
delayed gastric emptying
Clear Possible support in starting enteral 
feeding in patients receiving opioids
Side effects of opioid antagonists are 
mild to moderate with the approved 
dosing
Clear Overdosing may lead to more 
severe side effects without 
increasing efficacy
(Continued)Core Evidence 2009:4 248
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Scope, aims, and objectives
Cancer-related pain affects approximately 9 million people 
worldwide. As cancer progresses, an increasing fraction of 
patients require treatment with potent opioids, which may 
be administered via several routes. Opioid medication is fre-
quently used for the pain suffered by palliative care patients 
with malignancies. However, morphine and related opioids 
are associated with various side effects: constipation, nau-
sea, vomiting, pruritus, urinary retention, and so forth.1 
Constipation is the most commonly occurring adverse 
effect of chronic opioid therapy in patients with advanced 
cancer.2 It is an almost inevitable consequence of opioid 
use in cancer and nonmalignant disease states. Schug and 
colleagues showed that in patients with cancer, constipation 
and vomiting were the most common adverse effects asso-
ciated with opioid therapy.3 Unlike other adverse effects 
of opioid therapy, constipation is one of the side effects of 
opioids to which tolerance rarely develops.4 In most cases 
this problem is managed with stool softeners and laxatives. 
Presently, with the introduction of methylnaltrexone, it 
seems possible that a novel peripherally acting opioid 
antagonist can provide causal treatment for opioid-induced 
constipation (OIC), yet not interfere with the analgesic 
effect.
This review seeks to assess the scientific rationale for 
using methylnaltrexone to treat opioid-induced constipation 
and to discuss the current evidence for its therapeutic use.
Methods
We conducted a literature search on April 30, 2009 with 
OVID’s http://www.ovid.com interface of the following 
databases: MEDLINE (including Medline in Process and 
other nonindexed citations) 1950 to April 30, 2009, the 
multifile database EBM Reviews (including Cochrane 
Database of Systematic Reviews, Cochrane Central Register 
of Controlled Trials, Database of Abstracts of Reviews 
(Continued)
Outcome measure Evidence Implications
risk of abdominal cramping is higher 
with use of methylnaltrexone
Clear Abdominal cramping in mild to 
moderate intensity is a possible 
side effect
Avoiding enemas No evidence
Disease-oriented measurement
reversal of opioid-induced increased 
transit time in healthy individuals
Clear Concomitant medication of methyl-
naltrexone and opioids during 
anesthesia promising possibility, but 
until now no evidence for general use
reversal of opioid-induced increase 
in orocecal transit time
Clear Half the patients treated will expe-
rience a laxation within a few hours 
after the first application
Methylnaltrexone relieves 
constipation in chronic opioid-
treated patients with advanced illness
Clear Useful in patients used to opioids, 
who have a higher sensitivity to 
methylnaltrexone
Dose-dependent effect Clear Dosing according to body-weight, 
dose escalation not helpful
Efficacy without opioid withdrawal/
analgesic reduction
Clear No increase in opioid dosing 
necessary with methylnaltrexone 
treatment
Efficacy superior to laxatives No evidence No direct comparative trials have 
been performed
Maintenance of clinical response weak Efficacy of methylnaltrexone is 
unchanged at least during the 
3-month duration of therapy
reduced need for laxatives weak Additional laxatives may be 
required and continued
Economic evidence
Cost effectiveness compared with 
other laxatives
No evidence Long-term pharmacoeconomic 
studies are neededCore Evidence 2009:4 249
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of Effects, National Health Service Economic Evaluation 
Database) 1st quarter 2009, and BIOSIS Previews 1969 
to 2009 Week 30. Additional searches were performed in 
CINAHL http://search.ebscohost.com 1982 to date, Science 
Citation Index Expanded http://www.isiknowledge.com 
1945 to April 30, 2009, EMBASE (including EMBASE 
Alert) http://www.dimdi.de/static/de/db/dbinfo/em74.htm 
1974 to April 30, 2009, and PubMed http://www.ncbi.nlm.
nih.gov/entrez/query.fcgi?db=PubMed. No language restric-
tions were placed on the searches. The search terms included 
“methylnaltrexone”, “constipation”, “intestinal obstruction”, 
“opioid-induced bowel disease” and the Cochrane Highly 
Sensitive Search Strategy for identifying randomized 
trials.
Our search strategy consisted of 3 steps. After identifying 
articles on opioid-induced constipation, we added the search 
results for peripherally acting opioid antagonists and limited 
the search to clinical trials in human beings. In addition 
we scanned the reference lists of the identified studies and 
performed internet searches with the terms listed above 
using Scirus http://www.scirus.com and Google Scholar 
http://scholar.google.de. Further trials were identified in 
specialized registers such as Current Controlled Trials 
http://www.controlled-trials.com, WHO Clinical Trials 
Registry Platform ICTRP http://www.who.int/trialsearch, 
National Institutes of Health Randomized Trials Records 
http://clinicaltrials.gov, and the Clinical Trials Database 
of the Association of the British Pharmaceutical Industry 
http://abpi.org.uk. After excluding duplicates and clearly 
irrelevant references, a total of 21 relevant publications 
were identified.
Disease overview
Most cancer-related pain can be managed effectively using 
orally administered analgesics. Current pharmacotherapy is 
based on the World Health Organization (WHO) concept of an 
analgesic ladder.5 The ladder suggests that clinicians should 
start with a non-opioid and, if pain is not controlled, progress 
to a weak opioid and then to a strong opioid. For patients 
with moderate to severe pain, oral morphine is convention-
ally the opioid of choice.6 The WHO analgesic ladder has 
been extensively validated and guidelines for the use of oral 
morphine have been presented.7 This framework of principles 
allows for flexibility in the choice of analgesics. It is one part 
of a comprehensive strategy for managing cancer pain. Some 
types of pain, such as neuropathic pain, may be less responsive 
to opioids than other types of pain, such as nociceptive, soft 
tissue pain.8 Morphine still is the drug of choice for managing 
moderate to severe cancer pain. No drug has been shown to 
have greater analgesic efficacy. Morphine is also the most 
cost effective analgesic. Consequently, in 2005 opioids were 
prescribed about 365 million times worldwide.9
Successful opioid-therapy requires that the benefits of 
analgesia clearly outweigh treatment-related adverse effects. 
This implies that a detailed understanding of adverse opioid 
effects and the strategies used to prevent and manage them are 
essential skills for all involved in cancer pain management. 
Constipation and nausea are the most incriminating side 
effects of opioid treatment. There is striking variability in 
individual sensitivity to the adverse effects from morphine 
and other opioid drugs. Genetic variability clearly affects 
the sensitivity to opioid analgesia, particularly with regard 
to codeine, dihydrocodeine and possibly, oxycodone. And 
it is reasonable to assume that genetic backgrounds play 
a similarly important role in the predisposition to adverse 
effects.10 These side effects should be kept in mind when 
patients are being treated with strong analgesics such as 
opioids and the treatment guidelines mentioned above should 
be followed.
Opioid-induced bowel dysfunction is increasingly 
recognized as a significant clinical problem and pathophysi-
ological principles have been elucidated. Opioids inhibit 
propulsive gastrointestinal motility.11,12 Furthermore, there 
is increasing evidence that opiods have immunomodulatory 
effects,11,13,14 eg, the extended phase of postoperative ileus 
is caused by an enteric inflammatory response and recruit-
ment of leucocytes to the muscularis of the bowel wall. 
Table 1 Evidence base included in the review
Category Number of records
Full paper Abstracts
initial search 62 15
  records excluded 42 11
  records included 20 4
Additional studies identified 1 0
Total records included 21 4
Level 1 clinical evidence 
(systematic review, meta-analysis)
4 0
Level 2 clinical evidence (rCT) 13 4
Level 3 clinical evidence (trials 
without randomization, cohort)
4
Level 4 clinical evidence 
(observational studies)
Economic evidence 0 0
Notes: For definitions of levels evidence see inside back cover or Core Evidence 
website (http://dovepress.com/core-evidence-journal).
Abbreviation: rCT, randomized controlled trial.Core Evidence 2009:4 250
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Leucocytes produce the main inhibitory neurotransmitter of 
the gastrointestinal tract, nitric oxide, through the activity 
of the inducible isoform of nitric oxide synthase (iNOS).15 
Opioids potentate iNOS induction and nitric oxide release 
from phagocytes;16 therefore, blockage of this opioid-
mediated response might be of specific use in reversing 
postoperative ileus.11 Opioid-induced bowel dysfunction can 
lead to various gastrointestinal complications ranging from 
mild discomfort to fecal impaction, pseudo-obstruction, and 
bowel perforation.17,18 A recent survey suggests that severe 
opioid bowel dysfunction reduces the value of pain relief by 
more than 30%. In fact, many patients expressed a preference 
for uncontrolled pain over well-controlled pain with severe 
gastrointestinal adverse effects.17
Opioid-induced constipation can be exacerbated by 
metabolic alterations (diabetes, hypercalcemia, hypokalemia, 
uremia, hypothyreoidism), dehydratation, advanced age, 
reduced physical activity or immobility, low-fluid and/or 
low-fiber intake, difficulty reaching the bathroom, mechanical 
obstruction, neurological disorders, autonomic failure, drugs 
with anticholinergic action such as odansetron, diuretics, 
anticonvulsants, iron, vinca alkaloids, benzodiazepines 
and some antihypertensive drugs.10,19 The adverse effects 
of the other medications may be synergistic or cumulative 
to those associated with opioid medications and be due to 
an alteration in opioid absorption, metabolism or clearance 
of the opioid analgesics.20 Pharmacological interactions 
have to be considered. A change in medication may help in 
some cases. During the course of the disease, the physician 
has to distinguish between the adverse effects of morphine 
and the effects of co-morbidity or drug interactions.
Current therapy options
Gastrointestinal effects are the most common side effects 
of opioids. Opioid-induced bowel dysfunction affects the 
whole gut. It is often a greater problem for patients than pain. 
Nausea and emesis are common but usually resolve within 
days; prophylactic anti-emetics can help. Gastric stasis, sati-
ety, flatulence, and constipation persist in most of the cases. 
A prokinetic drug, such as metoclopramide, may also be 
employed to reduce gastric stasis.2 Constipation is predictable 
and occurs in at least 90% of the patients. It is characterized 
by accumulation of gas and secretions and by retention of 
bowel content, leading to hard stools, incomplete evacuation, 
bloating, pain, nausea, and vomiting. Opioid-induced bowel 
dysfunction can occur immediately after the first dose and 
persist for the duration of therapy. It demonstrates a very weak 
dose relationship, so dose reduction is often ineffective.
Most guidelines on the management of opioid-related 
constipation recommend co-prescribing both softening 
and stimulating laxatives containing opioids. Stimulating 
laxatives should be used with caution in patients at risk of 
bowel obstruction. Furthermore, the long-term effective-
ness and safety of such a regimen is unclear. There are 
no studies to indicate the superiority of one laxative over 
another in the management of opioid-induced constipation. 
Among the agents that have been suggested are docusate, 
senna, bisacodyl, phenolphthalein, and lactulose. Prospective 
data have demonstrated the efficacy of senna,21 sodium 
picosulfate,22 polyethylene glycol23 and oral naloxone.24 
However, naloxone may reverse the analgesia. Titration 
to determine the best balance between the reduction of 
adverse effects and a satisfactory analgesia is challenging. 
In one small series, opioid rotation of morphine to metha-
done resulted in a reduction in constipation.25 Reduction of 
constipation was not reported in one observational study 
on changing the route of morphine administration.26 Recent 
crossover studies have demonstrated a reduced tendency 
to constipation among patients treated with transdermal 
fentanyl in place of oral morphine.27–31
Unmet needs
Bowel dysfunction is one of the most distressing adverse effects 
associated with opioid administration.18 Opioid-induced 
bowel dysfunction encompasses a range of different 
gastrointestinal symptoms, including straining, hard stools, 
incomplete evacuation, abdominal distension, bloating, 
increased gastroesophageal reflux, and constipation.32 
Uncontrolled symptoms of opioid-induced bowel dysfunction 
can have a profound impact on the patient’s quality of life. 
While constipation is well recognized as a common and unre-
lentingly adverse drug reaction to opioids, the importance 
of the impact of opioid-induced constipation on a patient’s 
quality of life is generally not appreciated by healthcare 
professionals. Poor management of bowel dysfunction has 
a negative impact on a patient’s quality of life.
Multiple approaches have been described to address 
the problem of opioid-induced constipation demonstrating 
the lack of a superior approach.33 Frequently, nonopioid 
pharmacological strategies are used for treating constipa-
tion: bulking agents and laxatives. The main effect of 
laxatives is limited to the emptying of the colon. Laxatives 
rarely provide adequate relief for all the complaints of the 
patient and frequently induce nausea, bloating, flatulence, 
distension, abdominal discomfort, and cramping abdominal 
pain.34–36 Furthermore, their efficacy in opioid-induced Core Evidence 2009:4 251
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constipation has not been established.37,38 Centrally acting 
opioid antagonists often reverse the analgesic effects of 
opioid agonists in postoperative patients39–41 and produce 
withdrawal effects in patients on long-term opioid therapy, 
even in small doses.24,42 They are unsuitable for acute post-
operative patients and chronic opioid users.
Therefore, there is an urgent need for more effective, 
better tolerated, and safe treatments that normalize bowel 
function in patients with impaired bowel function due to 
opioid therapy. The clinical challenge of selecting the best 
option is enhanced by the lack of definitive, evidence-based 
comparative data.
The search for opioid antagonists that act locally in the 
gut and do not reverse analgesia has involved the reformu-
lation, or oral administration of existing antagonists, such 
as naloxone, and the development of new compounds. 
Peripheral opioid antagonists offer 2 distinct advantages 
for the prevention of opioid side effects: first, they do not 
reverse centrally mediated analgesia and secondly, a single 
drug may be used to prevent multiple adverse side effects.43 
Therefore, these drugs represent a potential advance in 
medical therapy.
Clinical evidence
A number of phase I and II studies have established the 
pharmacodynamic, pharmacokinetic, therapeutic, and 
safety profile of methylnaltrexone. In healthy volunteers, 
both the parenteral and oral formulations, as well as single 
and repeated dosage regimens, were found to be effective 
in preventing the morphine-induced prolongation of gastric 
emptying and orocecal transit time without significantly 
attenuating morphine-induced analgesia.17,44–50
The first pilot, single-blind study in 4 patients with 
long-term methadone-induced constipation revealed imme-
diate laxation and a dramatic reduction in orocecal transit 
time after intravenous (iv) application of methylnaltrexone 
(0.05 to 0.45 mg/kg iv).47 However, 1 of the 2 subjects 
given 0.45 mg/kg twice daily had to stop the therapy due 
to abdominal cramping and was removed from the study. 
The other 2 patients received escalating doses starting 
with 0.05 mg/kg over 10 minutes for 4 days. This dose 
was increased after 10 minutes to 0.1 mg/kg over 15 min, 
which caused an immediate laxation response in both 
patients. Doses of 0.05 to 0.15 mg/kg were equally effec-
tive for laxation and shortening of the orocecal transit time. 
Orocecal transit time was assessed by a lactulose breath test. 
The time between ingestion and the earliest detectable and 
sustained rise in pulmonary hydrogen excretion indicates 
that lactulose had reached the cecum and was recorded as 
the orocecal transit time. Stool frequency increased from 
1 to 2 occurrences per week to 1.5 occurrences per day in 
the three patients evaluated and the orocecal transit time 
decreased from 150 minutes after placebo to 60 to 90 minutes 
following methylnaltrexone treatment.
In a larger randomized controlled trial, the same group 
confirmed these findings without any signs of opioid with-
drawal.51 Twenty-two long-term methadone users were 
randomized to placebo or methylnaltrexone. The compound 
was administered intravenously as 9-minute infusions of 
increasing dosage from 0.015 to 0.05 and 0.1 to 0.2 mg/
kg body weight, with a 1-minute delay before the next 
dose, until the last dosage was given or the patient had a 
bowel movement. Ten out of the 11 patients treated with 
methylnaltrexone had immediate laxation responses during 
the day 1 afternoon session at a mean methylnaltrexone dose 
of 0.09 mg/kg, and all 11 subjects had immediate laxation 
during the day 2 morning session (P  0.001 vs placebo). 
No laxation response was observed in the 11 patients 
receiving placebo. During and immediately after each 
drug injection study, all subjects reported mild to moderate 
abdominal cramping, which they described as being similar 
to a defecation sensation, without discomfort. No opioid 
withdrawal symptoms were observed in any of these subjects 
during the study. No significant adverse effects were reported 
by the subjects. While baseline orocecal transit time did not 
differ significantly between the groups, the average change 
in transit times (±SD) for subjects in the methylnaltrexone 
group (n = 11) was -77.7 ± 37.2 minutes, significantly greater 
than that observed in the placebo group (–1.4 ± 12.0 minutes; 
P  0.001). Subjects in the treatment group were satisfied 
with their bowel movement activity. This trial demonstrates 
that individuals receiving long-term methadone treatment 
are much more sensitive to intravenous methylnaltrexone 
than healthy, opioid-naive subjects. In a phase I trial, healthy 
volunteers received up to 1.25 mg/kg methylnaltrexone.46 
The dose-limiting adverse effect in this study was transient 
and self-limited, orthostatic hypotension.
The utility of subcutaneous (sc) methylnaltrexone to 
selectively counteract opiate-induced stasis in the gastro-
intestinal tract has been proven in phase II and phase III 
studies of patients with advanced illness requiring high 
doses of opiates for pain control. The efficacy and dose-
response relationship of methylnaltrexone in relieving opi-
oid-induced constipation was first evaluated in a multicenter, 
randomized and parallel-group phase II trial involving 33 
adult patients with advanced illness (defined as terminal Core Evidence 2009:4 252
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or end-stage diseases such as metastatic cancer and AIDS) 
who were receiving chronic opioid therapy for pain on a 
daily basis.52 Patients were eligible for the study if they had 
a stable opioid drug dosage and no bowel movements for 
2 days, reporting ongoing constipation even if they received 
conventional laxative therapy. The schedule of repeated 
methylnaltrexone treatment included a double-blind phase 
for 1 week, followed by an open-label phase for a maximum 
of 3 weeks. In the first week, study medication was admin-
istered on days 1, 3, and 5 whereas open label therapy could 
be administered as often as every other day. The initial dose 
range of 1 mg, 5 mg, or 12.5 mg was extended by adding 
a 20 mg group during the study while still maintaining the 
double blind. Only one of 10 patients (10%) who received 
the 1 mg dose experienced laxation within 4 hours of dosing. 
The median time to laxation was 48 hours for the 1 mg 
dose group, compared to 1.26 hours for all patients receiving 
5 mg (P = 0.0003). There was no apparent increase in 
efficacy at doses above 5 mg. There were no changes in pain 
scores or evidence of opioid withdrawal.
Based on this study, 2 phase III trials of subcutaneous 
methylnaltrexone were conducted in patients suffering from 
opioid-induced constipation and end-stage diseases.53,54 In the 
first placebo-controlled, multicenter trial, methylnaltrexone 
(0.15 mg/kg) was given every other day for 2 weeks 
to 133 patients with advanced illness suffering from 
opioid-induced constipation. Eligible patients had a life 
expectancy of less than 6 months and opioid-induced 
constipation (less than 3 laxations in the prior week or no 
laxation in 48 hours); were receiving stable doses of laxatives 
and opioids; and were enrolled in hospice, nursing home, or 
palliative care programs. Patients were permitted to double 
the initial volume of the blinded study drug in week 2 if they 
had fewer than 3 rescue-free laxations (defined as laxation 
without the use of a rescue laxative, such as an enema or a 
suppository, after receipt of the study drug) in the first week. 
The double-blinded phase was followed by an open-label 
extension trial, during which patients received subcutane-
ous methylnaltrexone as needed up to every 24 hours for 
up to 3 months. The first open-label extension dose was 
administered more than 14 days after the first double-blind 
dose and more than 24 hours after the last double-blind dose. 
Subsequent doses could be increased to 0.30 mg/kg if no laxa-
tion occurred within 4 hours. The analysis of efficacy included 
133 patients (62 in the methylnaltrexone group). Forty-eight 
percent of the patients given methylnaltrexone had a rescue-
free laxation after receiving the first dose of the study drug 
compared with 15% in the placebo group (P  0.001). 
Significantly more patients in the methylnaltrexone group 
(52%) had rescue-free laxation within 4 hours after 2 or 
more of the first 4 doses, as compared with the placebo group 
(8%; P  0.001). This high rate of response to therapy was 
maintained throughout the 2-week double blind period and 
the 3-months extension period. The median time to laxa-
tion was approximately 30 minutes after administration of 
methylnaltrexone. Of the adverse events occurring in 5% 
or more of patients in either study group, abdominal pain, 
flatulence, nausea, increased body temperature, and dizziness 
occurred more frequently in the methylnaltrexone group with 
an increase in incidence of 3 percentage points or more over 
that in the placebo group. Adverse events that occurred more 
frequently in the placebo group than in the methylnaltrexone 
group included falls and hypotension. The pattern of adverse 
events in patients who had a dose escalation to 0.3 mg/kg 
during the second week showed no meaningful differences 
between groups. The key goal of this randomized controlled 
study was to demonstrate that methylnaltrexone could safely 
and reliably produce laxation, without reversing analgesia or 
inducing opioid withdrawal symptoms, as it has been shown 
earlier in individuals using methadone.55
A second study enrolled 154 patients with advanced 
illness and opioid-induced constipation in a double-blind, 
randomized placebo-controlled trial, with an optional 
open-label phase (up to 4 months) in hospice and palliative 
care centers.54 Participants received a single subcutaneous 
injection of methylnaltrexone (0.15 mg/kg or 0.3 mg/kg 
body weight) or a placebo. Laxation response within 4 hours 
was 62% and 58% for methylnaltrexone 0.15 mg/kg and 
0.3 mg/kg, respectively, compared with 14% for placebo 
(P  0.0001). For all patients, the median time to rescue-free 
laxation was 1.10 hours in the methylnaltrexone 0.15 mg/kg 
group, 0.8 hours in the 0.3 mg/kg methylnaltrexone group, 
and 24 hours in the placebo group. Approximately half of 
the methylnaltrexone responders defecated within 30 minutes 
of dosing. Open-label phase response rates mirrored those 
for methylnaltrexone during the double-blind phase. There 
was no change in pain scores or evidence of central opioid 
withdrawal.
Karver et al describe 124 cancer patients receiving either 
placebo (n = 42), methylnaltrexone 0.15 mg/kg (n = 37) or 
methylnaltrexone 0.3 mg/kg (n = 45).56 Patients had a life 
expectancy of 1 to 6 months, no laxation within 48 hours, 
and were maintained on stable opioids and baseline laxa-
tives. The primary efficacy endpoints were laxation within 
4 hours after a single dose of the study drug. 59.5% of the 
patients receiving methylnaltrexone 0.15 mg/kg and 55.6% Core Evidence 2009:4 253
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of those receiving 0.3 mg/kg had a rescue-free laxation 
within 4 hours compared to 16.7% in the placebo group 
(P = 0.0001). In another phase III study of this group, 
78 cancer patients received either 0.15 mg/kg sc qod meth-
ylnaltrexone for 2 weeks (total of 7 doses) or placebo.56 The 
primary efficacy endpoints were laxation within 4 hours after 
at least 2 of the first 4 doses of the study drug. A majority of 
the methylnaltrexone-treated cancer patients had a laxation 
within the first 4 hours after study-drug administration 
(51.4% of methylnaltrexone treated patients compared to 
14.6% in the placebo group, P = 0.0007). At least 2 laxations 
were observed in 59.5% of the treated patients during the 
4 hour period after the first 4 doses compared to 7.3% of the 
placebo group (P  0.0001).56 In both studies, no loss of 
pain control or opioid withdrawal was observed.
Other indications
A further phase II, double-blind, randomized placebo-controlled 
trial evaluated methylnaltrexone (0.3 mg/kg iv), administered 
every 6 hours for a maximum of 7 days, in 65 patients after 
segmental colectomy for the treatment of postoperative bowel 
dysfunction. Postoperative analgesics included morphine and 
fentanyl. The time to first bowel movement was significantly 
decreased in the methylnaltrexone group (98 ± 5.7 hours) 
compared to the placebo group (118 ± 10.3 hours; P = 0.038), 
as was the time to discharge eligibility (116.1 ± 6.9 versus 
148.7 ± 17.2 hours; P = 0.049). The time to toleration of 
full liquids, solid foods, and actual discharge were reduced, 
which favors treatment, but these effects did not reach 
statistical significance.57 Further randomized controlled 
studies are currently under way to clarify the impact of 
methylnaltrexone.
One hundred and twenty female patients undergoing lapa-
roscopic surgery under balanced anesthesia were included in a 
phase II study.58 Participants received either methylnaltrexone 
(20 mg iv) or a placebo at the end of surgery. The incidence of 
nausea was 27% and 20% for placebo and methylnaltrexone, 
respectively, and 18% and 10% of patients experienced 
emesis, respectively. These findings were not significant and 
suggested that methylnaltrexone did not prevent or reduce 
the incidence of nausea and emesis.
In a double-blind, randomized crossover trial, the 
effect of methylnaltrexone (0.3 mg/kg iv) on opioid 
(remifentanil)-induced bladder dysfunction was evaluated.59 
Thirteen healthy male volunteers received an intravenous) 
infusion of remifentanil, 0.15 µg/kg/minute, followed by 
a single intravenous dose of the study medication,meth
ylnaltrexone 0.3 mg/kg, naloxone 0.01 mg/kg, or saline). 
Urodynamics were measured with indwelling bladder and 
rectal catheters, and pupil size was assessed with infrared 
pupillometry. Remifentanil decreased detrusor pressure in 
21/25 sessions and caused complete urinary retention in 
18/25. Voiding was possible in 7/7, 5/12, and 0/6 sessions 
after naloxone, methylnaltrexone, and saline, respectively 
(P = 0.0013). Remifentanil caused marked miosis that was 
reversed by naloxone, but not methylnaltrexone or placebo 
(P  0.0001). Pupil data confirm that methylnaltrexone did 
not reverse the central opioid effects. Reversal of urinary 
retention by methylnaltrexone indicates that peripheral 
mechanisms may play a role in opioid-induced bladder 
dysfunction.
Opioids decrease the tone of gastric smooth muscles and 
increase the tone of sphincters. Gastric emptying is a function 
of both these effects. Two studies showed that methylnal-
trexone attenuates the morphine-induced delay of gastric 
emptying, suggesting that gastric emptying is a peripheral 
effect of opioids.45,60 Eleven healthy volunteers were given 
placebo, morphine (0.09 mg/kg), or a combination of mor-
phine and methylnaltrexone, and the rate of gastric emptying 
was measured by tests for bioimpedance and acetaminophen 
absorption.45 The time for 50% emptying was 5.5, 21.0, 
and 7.4 minutes after administration of placebo, morphine, 
and morphine/methylnaltrexone, respectively. Morphine 
delayed acetaminophen transfer from the stomach to the 
proximal jejunum and decreased the acetaminophen peak 
plasma concentration.45,60 These effects were also prevented 
by methylnaltrexone.45,60
Tolerability and safety
In a phase I study of 14 healthy volunteers, no adverse effects 
of clinical importance were observed after oral administra-
tion of up to 19.2 mg/kg body weight methylnaltrexone.44 
It was found that oral methylnaltrexone decreased the subjec-
tive ratings of skin itching and flushing caused by intravenous 
morphine.44,61 A low plasma bioavailability of oral methyln-
altrexone has been reported in these studies. This systemic 
bioavailability can be compared to that with naloxone, 
a commonly used opioid antagonist, in which systemic 
bioavailability after oral ingestion is only approximately 2% 
because of the high hepatic first-pass metabolism.62
As a charged compound, methylnaltrexone’s absorption 
in the gut may be limited, contributing in part to the low 
bioavailability. Less than 1% of the parent compound was 
excreted in the urine up to 6 hours after oral dosing, further 
suggesting a restricted absorption by the gut.44 In their study 
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for patients receiving long-term methadone therapy, Yuan 
and co-workers, found no significant side effects.55 Most 
patients reported very mild abdominal cramping after oral 
methylnaltrexone, which they described as similar to a 
defecation sensation without discomfort. However, in this 
study 8 of 12 enrolled participants had undetectable plasma 
methylnaltrexone levels.
Twelve healthy volunteers were given methylnaltrexone 
intravenously at doses of 0.45 mg/kg, placebo or morphine 
(0.05 mg/kg).17 No adverse effects of clinical importance were 
observed in this study. In another trial, methylnaltrexone was 
administered intravenously, up to a dosage of 0.365 mg/kg, 
to patients chronically using methadone.51 No significant 
adverse effects were mentioned.
In another study methylnaltrexone was applied to 
healthy male volunteers in 6 ascending doses with a placebo 
randomly inserted into the sequence. Each participant was 
observed for subjective and hemodynamic changes. The 
dose-limiting effect of intravenous methylnaltrexone was 
orthostatic hypotension at 0.64 mg/kg (N = 3) or 1.25 mg/kg 
(N = 5), which was transient and self-limiting. Plasma levels 
of methylnaltrexone in excess of 1.400 ng/mL were observed 
to be associated with orthostatic hypotension. There were no 
significant, subjective changes, no release in histamine, and 
no changes at physical examination or in laboratory results 
during the course of this study.46 Pharmacokinetic analyses 
revealed an elimination half life of 117.5 ± 53.2 minutes and 
a clearance of 38.8 ± 17.4 L/hour, with a methylnaltrexone 
dose of 0.64 mg/kg iv.
In most of the studies concerning patients with advanced 
illness, subcutaneous application has been used, doses 
ranging from 0.1 mg/kg to 0.3 mg/kg.49,53,54 Evidence of 
withdrawal mediated by central nervous system opioid 
receptors or changes in pain scores were not observed. 
Abdominal pain (in up to 45% of patients) and flatulence were 
the most common adverse effects, being mild to moderate and 
dose dependent. Slatkin et al describe severe adverse events 
occurring during the open-label phase of their study.54 One 
patient had flushing, another had delirium possibly related 
to methylnaltrexone, and a third patient had severe diarrhea 
with subsequent dehydration and cardiovascular collapse 
and death.
Although methylnaltrexone was significantly more 
effective than the placebo (at least 3 times as effective), it 
is somewhat disappointing that rescue-free laxation will 
happen only in about half of the patients. There may be 
several reasons for this failure. First, the predominant causes 
of constipation among the patients who did not respond to 
methylnaltrexone therapy could have been caused by other 
drugs or disease processes unrelated to actions mediated by 
opioid receptors. Second, central actions of opioids contribute 
as well, having not been modified by a peripherally acting 
antagonist.
The half-life of subcutaneously administered methyln-
altrexone is about 8 hours. Methylnaltrexone is primarily 
eliminated as an unchanged drug (85% of the administered 
dose). Approximately one-half of the dose is excreted in urine 
and less in feces.17,46,50,55 Methylnaltrexone is also metabolized 
into 5 distinct metabolites. N-demethylation to naltrexone is 
not significant.
Drug interactions
Methylnaltrexone is a weak inhibitor of CYP450 2D6 
in vitro; however, in vivo, it has not affected the metabo-
lism of the CYP2D6 substrate dextromethorphan. In vitro, 
it does not inhibit CYP1A2, CYP2A6, CYP2C9, CYP2C19, 
or CYP3A4. The potential for drug interactions with agents 
that are actively secreted by the kidney has not been studied 
in humans.63
Economic evidence for the use 
of methylnaltrexone
There is a clinical need for effective treatment of opiate-
induced constipation, because constipation is not only a 
frequent but also a distressing symptom.1 Any measure that 
improves the tolerability of opioid analgesics represents 
progress in the treatment of pain.64 The use of methyln-
altrexone concurrent with opioid therapy in patients with 
chronic malignancy-associated pain may reduce the burden 
of hospice, nursing home and palliative care programs to 
provide patient care. However, there are no published data on 
the assessment of resource utilization with methylnaltrexone 
for opioid-induced bowel dysfunction in patients with 
advanced illness.
Patient group/population
Methylnaltrexone is approved by the US Food and Drug 
Administration (FDA) to help restore bowel function in 
patients with late-stage, advanced illness who are receiving 
continuous opioids; that is, methylnaltrexone is a treatment 
for opioid-induced bowel dysfunction, when response to 
laxatives has not been sufficient.
In this context it is worth noting, that methylnaltrexone 
is also able to ameliorate opioid-induced urinary retention,59 
itching and nausea. There is some weak evidence that 
methylnaltrexone may relieve postoperative ileus.Core Evidence 2009:4 255
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Methylnaltrexone does not reverse opioid-mediated 
ventilatory depression, a centrally mediated opioid effect.65 
Therefore methylnaltrexone cannot be used, like naloxone, 
to treat patients with an opioid overdose.
Dosage, administration, 
and formulations
The drug has been formulated as a solution for intravenous or 
subcutaneous administration and as capsules/tablets for oral 
administration. Both the parenteral and oral formulations, 
as well as single and repeated dosage regimens, have been 
found to be efficacious in preventing the morphine-induced 
prolongation of gastric emptying and orocecal transit 
time without significantly attenuating morphine-induced 
analgesia.66–68 The drug has been approved for subcutaneous 
application which ensures ease of use in both the hospice and 
home setting, in contrast to intravenous drug administration. 
Methylnaltrexone was approved by the FDA in April 2008 
to help restore bowel function in patients with late-stage, 
advanced illness who are continually receiving opioids, when 
response to laxative therapy has not been sufficient. It is also 
approved by Health Canada and the European Medicine 
Agency. The recommended dosage is 8 mg every other day 
for a body weight between 38 to 62 kg and 12 mg every other 
day for a body weight of 63 to 114 kg. For a body weight 
beyond these outlines, the dose in mg should be calculated 
as 0.15 mg × body weight in kilograms. It should not be 
dispensed more frequently than 1 dose in a 24-hour period.63 
It should be administered as a subcutaneous injection in the 
upper arm, abdomen, or thigh.63 Methylnaltrexone is contra-
indicated in patients with known or suspected mechanical 
intestinal stenosis or acute abdominal distress.
Further clinical studies are needed to define, long term, 
the optimal dosage, optimal dosing regimen, and the optimal 
efficacy/safety profile of methylnaltrexone. The therapeutic 
value of methylnaltrexone cannot be fully appreciated before 
its long-term efficacy and safety record have been disclosed. 
Since methylnaltrexone is likely to be used in multimorbid 
patients, its interaction with other drugs and the necessity 
of dose adjustment in patients with renal insufficiency or 
failure also need to be determined.68 In patients with severe 
renal function impairment (creatinine-clearance less than 
30 mL/minute), the dose should be reduced by one-half.63 
There are no data available for its use in young patients.
Methylnaltrexone for subcutaneous injection is available 
as a 12 mg per 0.6 mL solution in singleuse vials. Product 
excipients are sodium chloride 3.9 mg, edentate calcium 
disodium 0.24 mg, glycine hydrochloride 0.18 mg, and 
hydrochloric acid and/or sodium hydroxide to adjust pH. The 
product will be available in prefilled syringes at a later date. 
Storage is recommended at room temperature (20° to 25°C; 
68° to 72°F); excursions are permitted between 15° and 30°C 
(59° and 86°F). The compound should be protected from 
light. Once drawn into a syringe, if immediate administration 
is not possible, the product should be stored at room 
temperature and administered within 24 hours; protection 
from light is not necessary during this period.63
Place in therapy
Opioid analgesics are the mainstay therapy for moderate-
to-severe pain in patients with serious illness. Side effects, 
such as constipation, nausea, and vomiting, may be disabling 
to such a degree that opioid treatment needs to be reduced 
or even abandoned. The traditional approach to ameliorate 
opioid-induced constipation is laxative co-medication 
which, however, can be both ineffective and distasteful to 
the patient. The majority of the currently available treat-
ments are relatively ineffective in this context and have not 
been tested in well-controlled modern trials. A major limi-
tation of chronic treatment with laxatives, however, is that 
although they increase stool frequency, they do not relieve 
all the constipation-associated symptoms such as bloating, 
abdominal discomfort, and pain, resulting in poor compliance. 
They also may induce troublesome adverse events including 
flatulence, bloating, and abdominal cramping pain.69
The spectrum of adverse opioid actions on the gut reflects 
the ability of these analgesic drugs to directly interact with 
the pathways of the enteric nervous system which regulates 
gastrointestinal motility and secretion. In addition, there 
is evidence that opioid receptors in the brain can cause 
gastrointestinal effects. However, experimental and clinical 
studies with opioid-receptor antagonists that are unable to 
enter the brain have shown that the adverse gastrointestinal 
effect profile of opioid receptor antagonists is essentially of 
a peripheral origin. Methylnaltrexone is a member of a new 
class of peripherally acting µ-receptor opioid antagonist 
drugs. The addition of a methyl group to the naltrexone 
molecule makes methylnaltrexone positively charged and 
hydrophilic, thereby preventing transport across the blood–
brain barrier. Hence it neither reverses central nervous system 
opioid analgesia nor causes withdrawal in opioid-tolerant 
patients. Methylnaltrexone, administered subcutaneously, 
has recently been approved by the FDA, as well as by Health 
Canada and the European Medicines Agency. In the United 
States, it is indicated for the treatment of opioid-induced 
constipation in patients with advanced illness (eg, cancer, Core Evidence 2009:4 256
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AIDS) who are receiving palliative care, when response to 
laxative therapy has not been sufficient.
Methylnaltrexone is well tolerated and remained effective 
in randomized controlled trials of up to 16 weeks. The 
heterogeneity of dosage regimens and routes of administra-
tion make it difficult to suggest an optimal approach. The 
effects on stool frequency, constipation-associated symptoms 
as well as adverse effects are dose related. There was no 
further improvement in efficacy above a dose of 0.3 mg/kg. 
The percentages of responders to 0.15 and 0.3 mg/kg appear 
to be similar, the latter being combined with a higher rate 
of adverse events. A single daily dose appears appropriate, 
being followed by subsequent doses every other day. Only 
if there is no response to therapy would daily application 
be suggested. The response rate in patients with advanced 
illness is supposed to be between 50% and 60%,53,54 half 
of the patients responding within 30 minutes after drug 
administration.
At therapeutic doses (0.3 to 0.45 mg/kg iv and up to 
19.2 mg/kg orally) methylnaltrexone is well tolerated, an 
outcome that is also true when methylnaltrexone is repeatedly 
administered at 0.3 mg/kg iv every 6 hours. The incidence 
of adverse reaction with the opioid antagonist is similar to 
placebo and generally reported as mild to moderate.70 The 
main adverse reactions being reported relate to the vascular or 
the gastrointestinal system. Transient orthostatic hypotension 
can occur at supra-therapeutic doses.64,66–68 This reaction may 
cause the facial flushing and mild light-headedness, symptoms 
that have occasionally been reported. The other type of adverse 
effect comprises gut-related reactions, such as abdominal 
cramping, soft stools, and diarrhea.50,64,66–68
The preliminary data on improvement of gastric emptying 
in opioid-receiving patients indicate that methylnaltrexone 
could have further advantages.45 By decreasing the volume 
of gastric contents, methylnaltrexone may decrease the risk 
of regurgitation and pulmonary aspiration. This effect may 
be of particular importance in patients undergoing general 
anesthesia. Because the esophageal sphincter is relaxed and 
the patients are in a supine position, protective airway reflexes 
are absent. Furthermore, methylnaltrexone may increase that 
drug’s rate of absorption and peak concentration by increas-
ing the rate at which an orally administered drug passes into 
the proximal small bowel and by decreasing gastric residuals. 
In the same way methylnaltrexone may support the effort 
for enteral readings to be administered to patients who are 
taking large doses of opioids – an effect that may be of great 
importance for patients in the intensive care unit who are 
taking large doses of opioids. No controlled studies of the 
effects of methylnaltrexone on enteral nutrition have been 
conducted. However, one case report describes the successful 
use of methylnaltrexone to initiate feedings in a patient with 
a 30% burn.71 Peripheral opioid antagonists also may be 
useful for treating and avoiding nausea and vomiting, other 
well-known adverse effects of opioids that may have both 
peripheral and central components. In one small study, meth-
ylnaltrexone markedly attenuated the nausea associated with 
parenteral morphine administration.49 In another small study, 
patients who received methylnaltrexone for reversal of opioid 
urinary effects had a decrease in vomiting compared with 
those who received placebo.59 This decrease in vomiting may 
have resulted from an action at the chemoreceptor trig-
ger zone receptors or a modulation of afferent impulses 
from the enteric nervous system to the brain.72 However, 
another study58 did not show an effect on the prevention of 
postoperative nausea.
In conclusion, methylnaltrexone has been proven to 
be effective for treatment of opioid-induced constipation. 
Eventually it may prove useful for managing cases of 
opioid-induced nausea and vomiting, post-operative ileus, 
enteral feeding, pruritus, and urinary retention. However, on 
the latter indications data are very preliminary and require 
further evidence.
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